Safety and Effectiveness of Tislelizumab with Platinum Chemotherapy for First Treatment of Lung Adenocarcinoma with Asymptomatic Brain Metastases

What this Trial Is About

This research aims to study the safety and effectiveness of combining Tislelizumab, a PD-1 inhibitor, with platinum-containing chemotherapy drugs as the first-line treatment for patients with lung adenocarcinoma who have asymptomatic brain metastases. The study also explores related biomarkers to better understand treatment response and resistance mechanisms in this patient population. Lung cancer spreading to the brain is a serious condition requiring new treatment approaches. Participants will receive induction therapy where Tislelizumab combined with platinum-based chemotherapy is given every three weeks, expected for six cycles. Patients who show complete response, partial response, or stable disease after this phase may enter a maintenance treatment period to continue monitoring their condition. The study involves only one treatment group receiving this combination therapy. Throughout the study, participants will be assessed for progression-free survival up to one year as the primary outcome. Additional measures include the objective response rate during approximately 12 months. Patients will undergo regular evaluations including imaging to measure tumor response and safety monitoring. The study lasts until the end date in December 2026, with careful tracking of participants health and treatment effects.

Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic